



Collaborative Working Executive Summary

Published on www.bayer.co.uk

Project title	Joint Working Project Improving the Quality and Journey of Prostate Cancer Patients at Mid and South Essex NHS Foundation Trust by the introduction of a Non-Medical Prescribing Pharmacist
Project partners	Mid and South Essex NHS Foundation Trust Bayer plc
Project summary	<p>The aim of the project is to increase capacity and provide rapid access to prostate cancer services through the introduction of a non-medical prescribing pharmacist who will lead additional outpatient clinics to reduce backlog.</p> <p>The new clinics led by the non-medical prescribing pharmacist will manage metastatic and non-metastatic patients who are on therapy for the management of their disease and who are not complex.</p> <p>This will mean fewer patients in the consultant led clinics, enabling the consultants to dedicate more time to each of the more complex metastatic prostate cancer patients. This would ensure that all patients have the required amount of time with the appropriate healthcare professional.</p>
Expected benefits to patients/patient care/NHS and Bayer	<p>Expected benefits for patients are:</p> <ul style="list-style-type: none">• Aims to increase rapid access to prostate cancer services by increasing available appointments per week• Aims to enable more complex patients to have an appropriate amount of time with consultants during clinic• Aims to improve prostate cancer patients' awareness of service options available through appropriate patient communications• Intends to create a thorough understanding of their disease state and aid self-management and adherence to treatment through improved patient counselling by the non-medical prescribing pharmacist

	<p>Expected benefits for the Trust are:</p> <ul style="list-style-type: none"> • Aims to facilitate the following service improvements: <ul style="list-style-type: none"> ○ Support reduction of clinic backlogs and waiting lists for prostate cancer reviews; ○ Enable the consultant to have sufficient time with complex cases; ○ Ensure patients are seen in the most appropriate clinic for their level of need, improving efficiency and the overall patient experience • Opportunity to share outputs, best practice and learning through a publication within the Oncology community illustrating the Oncology Pharmacist led out-patient clinic service development and quality of care improvements to provide evidence for a long-term financially sustainable service nationally in the oncology community <p>Expected benefits for Bayer are:</p> <ul style="list-style-type: none"> • Aims to demonstrate a successful partnership with the NHS team on a collaboration, which has the potential to be shared and adopted by other Hospital / NHS sites • Aims to gain a richer understanding of planning and implementing prostate cancer services within the context of Oncology Pharmacist Non-Medical Prescriber led out-patient clinic service innovation. This will enrich Bayer's discussions with other Hospital / NHS sites when developing other Collaborative Working Projects • Increasing capacity and efficiency aims to ensure treatment is in line with NICE guidelines (Bayer has a NICE approved treatment in this therapy area) • Opportunity to share outputs, best practice and learning from the collaboration within the oncology community to support service improvement in other locations • Aims to increase quality of care and patient satisfaction which aims to help patients increase compliance and adherence to treatment
Start date	December 2025

Date of Preparation: November 2025

Job bag number: PP-UN-ONC-GB-0173